NCT05228613CompletedPhase 1
A Phase I, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Adjuvanted With Alum+CpG 1018) in Healthy Populations Aged 18 Years and Above in Indonesia
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- PT Bio Farma
- Enrollment
- 175
- Locations
- 2
- Primary Endpoint
- Safety of the vaccine within 7 days after each dose
Study Overview
Brief Summary
The study is an observer-blind, randomized, controlled prospective intervention study of Phase I. The primary objective is to evaluate the safety and immunogenicity of the SARS-CoV-2 protein subunit recombinant vaccine adjuvanted with Alum+CpG1018
Detailed Description
This trial is observer blinded, comparative, randomized, phase I study. Approximately 175 subjects will be recruited (18 years and above).
The investigational product is 0.5 ml in two dose-regimen (for all subjects) with 28 days apart between doses, compare to an active control (inactivated SARS-CoV-2 vaccine). There will be 4 formula of investigational product used with different concentration of Receptor Binding Domain (RBD) antigen and adjuvant CpG 1018.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Masking Description
Observer blind: Investigational Product and Active Comparator are masking. Lot number is masking
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Clinically healthy subjects aged 18 years and above.
- •Subjects have been informed properly regarding the study and signed the informed consent form.
- •Subjects will commit to comply with the instructions of the investigator and the schedule of the trial.
Exclusion Criteria
- •Subjects concomitantly enrolled or scheduled to be enrolled in another trial.
- •History of vaccination with any investigational product against COVID-19 (based on anamnesis)
- •Subjects who have history of COVID-19 (based on anamnesis or other examinations).
- •Evolving mild, moderate or severe illness, especially infectious disease or fever (body temperature ≥37.5℃, measured with infrared thermometer/thermal gun).
- •The result of RT-PCR test for SARS-CoV-2 is positive.
- •Women who are lactating, pregnant or planning to become pregnant during the study period (judged by self-report of subjects and urine pregnancy test results).
- •Abnormality hematology and biochemical test results (for main study subset).
- •History of asthma, history of allergy to vaccines or vaccine ingredients, and severe adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema.
- •History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection.
- •Patients with serious chronic diseases (serious cardiovascular diseases, uncontrolled hypertension and diabetes, liver and kidney diseases, malignant tumors, etc) which according to the investigator might interfere with the assessment of the trial objectives.
- •Subjects who have any history of confirmed or suspected immunosuppressive or immunodeficient state, or received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long-term corticosteroid therapy (> 2 weeks)).
- •Subjects who have history of uncontrolled epilepsy or other progressive neurological disorders, such as Guillain-Barre Syndrome.
- •Subjects receive any vaccination (other than COVID-19 vaccine) within 1 month before and after IP immunization.
- •Subjects plan to move from the study area before the end of study period.
Outcomes
Primary Outcomes
Safety of the vaccine within 7 days after each dose
Time Frame: 7 days after each dose
percentage of subjects with solicited and unsolicited Adverse Events (AE)
Secondary Outcomes
- Serious Adverse Event (SAE) of the vaccine(6 months after the last dose)
- safety of the vaccine within 28 days after each dose(28 days after each dose)
- Inflammatory factor evaluation(7 days after the first dose and 14 days after the last dose)
- Immunogenicity profile after the last dose(14 days and 28 days after the last dose)
- Comparison of safety between vaccine and active control(28 days after each dose and 6 months after the last dose)
- Deviation of laboratory evaluation(7 days after the first dose and 14 days after the last dose)
- Comparison of immunogenicity profile(14 days and 28 days after the last dose)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant VaccineCovid19NCT05067894PT Bio Farma54
Completed
Phase 1
Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy AdultsInfluenza, HumanNCT06028347Seqirus96
Completed
Phase 1
The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)Herpes ZosterNCT05769049Jiangsu Rec-Biotechnology Co., Ltd.48
Not yet recruiting
Phase 1
Phase I Clinical Trial of a Candidate Herpes Zoster VaccineHerpes ZosterNCT05718037Wuhan BravoVax Co., Ltd.40
Completed
Phase 1
Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's DiseaseAlzheimer's DiseaseNCT02600130Longeveron Inc.33